Maraviroc (UK-427,857)
Sponsors
ViiV Healthcare
Conditions
HIVHIV Infections
Phase 2
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
CompletedNCT00098306
Start: 2004-11-30End: 2011-04-30Updated: 2012-04-27
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
CompletedNCT00098748
Start: 2004-11-30End: 2009-04-30Updated: 2010-12-07
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
CompletedNCT00098722
Start: 2004-12-31End: 2011-04-30Updated: 2012-05-16
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
CompletedNCT00634959
Start: 2003-07-31End: 2003-12-31Updated: 2010-11-10
Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
CompletedNCT00643643
Start: 2002-10-31End: 2003-06-30Updated: 2010-11-10